MedWatch

Biogen slashes price of controversial Alzheimer's drug

After a slow start for its Alzheimer's treatment, Aduhelm, US-based Biogen is attempting to kick-start sales by halving the price.

Photo: BRIAN SNYDER/REUTERS / X90051

US-based Biogen has dropped the price of its Alzheimer's treatment Aduhelm by fifty percent, Bloomberg News reports.

This has happened to light a fire under the sales, which have stagnated since the product's launch, partially because of its high price tag.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs